Cargando…
Towards a Patent Pool for HIV Medicines: The Background
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Open
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817875/ https://www.ncbi.nlm.nih.gov/pubmed/20148090 http://dx.doi.org/10.2174/1874613601004020033 |